PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project

Journal of Thoracic Oncology

Volumn 12, Issue 2, 2017, Pages 208-222

  Hirsch, Fred R ^a,b   McElhinny, Abigail ^c   Stanforth, Dave ^d   Ranger Moore, James ^e   Jansson, Malinka ^d   Kulangara, Karina ^d   Richardson, William ^e   Towne, Penny ^e   Hanks, Debra ^d   Vennapusa, Bharathi ^e   Mistry, Amita ^e   Kalamegham, Rasika ^f,g   Averbuch, Steve ^h   Novotny, James ^h   Rubin, Eric ⁱ   Emancipator, Kenneth ⁱ   McCaffery, Ian ^g,j   Williams, J Andrew ^g   Walker, Jill ^k   Longshore, John ^l   Tsao, Ming Sound ^m   Kerr, Keith M ⁿ   more..

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b International Association for the Study of Lung Cancer   (United States)

^c Personal Genome Diagnostics   (United States)

^d AGILENT TECHNOLOGIES   (United States)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

^f American Association of Colleges for Teacher Education   (United States)

^g GENENTECH INC   (United States)

^h BRISTOL MYERS SQUIBB   (United States)

ⁱ MERCK RESEARCH LABORATORIES   (United States)

^j Oncology Biomarkers Development ^*  (United States)

^k ASTRAZENECA   (United Kingdom)

^l LEVINE CANCER INSTITUTE   (United States)

^m PRINCESS MARGARET HOSPITAL   (Canada)

ⁿ UNIVERSITY OF ABERDEEN   (United Kingdom)

more..

Author keywords

Immunohistochemistry; Immunotherapy; Lung cancer; PD L1 assays

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1; MONOCLONAL ANTIBODY; TUMOR MARKER;

ALGORITHM; ARTICLE; CANCER INHIBITION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DECISION MAKING; FEASIBILITY STUDY; HUMAN; IMMUNOHISTOCHEMISTRY; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCORING SYSTEM; VALIDATION PROCESS; BIOASSAY; CLINICAL TRIAL; IMMUNOLOGY; LUNG TUMOR; METABOLISM; MULTICENTER STUDY; PATHOLOGY; PROCEDURES; PROGNOSIS;

ANTIBODIES, MONOCLONAL; B7-H1 ANTIGEN; BIOLOGICAL ASSAY; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; PROGNOSIS;

EID: 85015345322     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.11.2228     Document Type: Article

References (34)

1. 1 Gettinger, S.N., Kowanetz, M., Koeppen, H., et al. Molecular, immune and histopathological characterization of NSCLC based on PDL1 expression on tumor and immune cells and association with response to the anti-PDL1 antibody MPDL3280A. [abstract] J Clin Oncol, 33(suppl), 2015, 3015.
2. 2 Garon, E.B., Rizvi, N.A., Hui, R., et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372 (2015), 2018–2028.
3. 3 Herbst, R.S., Baas, P., Kim, D.W., et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387 (2016), 1540–1550.
4. 4 Borghaei, H., Paz-Ares, L., Horn, L., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373 (2015), 1627–1639.
5. 5 Rizvi, N.A., Mazieres, J., Planchard, D., et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 16 (2015), 257–265.
6. 6 Brahmer, J., Reckamp, K.L., Baas, P., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373 (2015), 123–135.
7. 7 Rizvi, N.A., Brahmer, J.R., Ou, S.-H.I., et al. Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). [abstract] J Clin Oncol, 33(suppl), 2015, 8032.
8. 8 Spigel, D.R., Chaft, J.E., Gettinger, S.N., et al. Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1-selected patients with non-small cell lung cancer (NSCLC). [abstract] J Clin Oncol, 33(suppl), 2015, 8028.
9. 9 Fehrenbacher, L., Spira, A., Ballinger, M., et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387 (2016), 1837–1846.
10. 10 Herbst, R.S., Soria, J.C., Kowanetz, M., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515 (2014), 563–567.
11. 11 Merck and Company, Inc. FDA approves Merck's KEYTRUDA (pembrolizumab) in metastatic NSCLC for first-line treatment of patients whose tumors have high PD-L1 expression (tumor proportion score [TPS] of 50 percent or more) with no EGFR or ALK genomic tumor aberrations. http://wwwmercknewsroomcom/news-release/prescription-medicine-news/fda-approves-mercks-keytruda-pembrolizumab-metastatic-nsclc-. Accessed November 10, 2016.
12. 12 U.S. Food and Drug Administration. Nivolumab (Obdivo). http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm436566.htm. Accessed November 10, 2016.
13. 13 U.S. Food and Drug Administration. FDA approves Keytruda for advanced non-small cell lung cancer. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm465444.htm. Accessed November 10, 2016.
14. 14 Roche: Media release: Roche receives FDA approval for novel PD-L1 biomarker assay. http://www.ventana.com/pd-l1-biomarker-assay-news. Accessed November 10, 2016.
15. 15 Dako PD-L1 IHC 28-8 pharmDX IFU. http://www.agilent.com/en-us/products/pharmdx/pd-l1-ihc-28-8-overview. Accessed November 10, 2016.
16. 16 Dako PD-L1 IHC Pharm testing. http://www.agilent.com/en-us/products/pharmdx/pd-l1-ihc-22c3-pharmdx-testing. Accessed November 10, 2016.
17. 17 Kerr, K.M., Tsao, M.S., Nicholson, A.G., et al. Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art?. J Thorac Oncol 10 (2015), 985–989.
18. 18 Cagle, P.T., Bernicker, E.H., Challenges to biomarker testing for PD-1/PD-L1 checkpoint inhibitors for lung cancer. Arch Pathol Lab Med 139 (2015), 1477–1478.
19. 19 Kerr, K.M., Hirsch, F.R., Programmed death ligand-1 immunohistochemistry: friend or foe?. Arch Pathol Lab Med 140 (2016), 326–331.
20. 20 U.S. Food and Drug Administration. A blueprint proposal for companion diagnostic comparability. http://www.fda.gov/downloads/MedicalDevices/NewsEvents/WorkshopsConferences/UCM439440.pdf. Accessed November 10, 2016.
21. 21 Phillips, T., Simmons, P., Inzunza, H.D., et al. Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer. Appl Immunohistochem Mol Morphol 23 (2015), 541–549.
22. 22 Roach, C., Zhang, N., Corigliano, E., et al. Development of a companion diagnostic PD-L1 immunohistochemistry assay for pembrolizumab therapy in non-small-cell lung cancer. Appl Immunohistochem Mol Morphol 24 (2016), 392–397.
23. 23 Rebelatto, M.C., Midha, A., Mistry, A., et al. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma. Diagn Pathol, 11, 2016, 95.
24. 24 Ilie, M., Long-Mira, E., Bence, C., et al. Comparative study of the PD-L1 status between surgically resectedspecimens and matched biopsied of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol 27 (2016), 147–153.
25. 25 Scheel, A.H., Dietel, M., Heukamp, L.C., et al. Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Mod Pathol 29 (2016), 1165–1172.
26. 26 Ruschoff, J., Kerr, K.M., Grote, H.J., et al. Reproducibility of immunohistochemical scoring for epidermal growth factor receptor expression in non-small cell lung cancer: round robin test. Arch Pathol Lab Med 137 (2013), 1255–1261.
27. 27 Fitzgibbons, P.L., Bradley, L.A., Fatheree, L.A., et al. Principles of analytic validation of immunohistochemical assays: guideline from the College of American Pathologists Pathology and Laboratory Quality Center. Arch Pathol Lab Med 138 (2014), 1432–1443.
28. 28 Lin, F., Chen, Z., Standardization of diagnostic immunohistochemistry: literature review and geisinger experience. Arch Pathol Lab Med 138 (2014), 1564–1577.
29. 29 Dolled-Filhart, M., Roach, C.M., Toland, G., et al. Development of a PD-L1 immunohistochemistry (IHC) assay for use as a companion diagnostic for pembrolizumab (MK-3475) in non-small cell lung cancer (NSCLC). [abstract] J Clin Oncol, 33(suppl), 2015, 11065.
30. 30 Rebelatto, M., Mistry, A., Sabalos, C., et al. Development of a PD-L1 companion diagnostic assay for treatment with MEDI4736 in NSCLC and SCCHN patients. [abstract] J Clin Oncol, 33(suppl), 2015, 8033.
31. 31 Neuman, T., London, M., Kania-Almoq, J., et al. A harmonization study for the use of 22C3 PD-L1 immunohistochemical staining on Ventana's platform. J Thorac Oncol 11 (2016), 1863–1868.
32. 32 Ibrahim, M., Parry, S., Wilkinson, D., et al. ALK Immunohistochemistry in NSCLC: discordant staining can impact patient treatment regimen. J Thorac Oncol 11 (2016), 2241–2247.
33. 33 Wolff, A.C., Hammond, M.E., Schwartz, J.N., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathology Lab Med 131 (2007), 18–43.
34. 34 Patel, S.P., Kurzrock, R., PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 14 (2015), 847–856.